A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of HTD1801 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis Who Have Type 2 Diabetes (T2DM) or Pre-Diabetes
Latest Information Update: 04 Jun 2025
At a glance
- Drugs Berberine ursodeoxycholate (Primary)
- Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CENTRICITY
- Sponsors HighTide Biopharma
Most Recent Events
- 30 May 2025 Status changed from active, no longer recruiting to completed.
- 27 Jan 2025 Planned End Date changed from 31 Mar 2025 to 30 Jun 2025.
- 27 Jan 2025 Planned primary completion date changed from 31 Mar 2025 to 30 Apr 2025.